Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have received a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $15.40.

A number of research analysts have recently issued reports on KPTI shares. Royal Bank Of Canada dropped their price target on shares of Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 4th. Robert W. Baird cut their price target on shares of Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating on the stock in a research report on Thursday, October 9th. HC Wainwright upgraded Karyopharm Therapeutics from a “neutral” rating to a “buy” rating and set a $15.00 price target for the company in a report on Monday, October 13th. Wall Street Zen raised Karyopharm Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Piper Sandler restated an “overweight” rating and set a $12.00 target price (down previously from $15.00) on shares of Karyopharm Therapeutics in a research report on Thursday, October 9th.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. T. Rowe Price Investment Management Inc. acquired a new stake in Karyopharm Therapeutics in the first quarter worth $523,000. XTX Topco Ltd bought a new position in shares of Karyopharm Therapeutics during the 2nd quarter worth about $56,000. Bank of America Corp DE boosted its position in shares of Karyopharm Therapeutics by 26.8% during the 2nd quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock worth $726,000 after purchasing an additional 35,626 shares in the last quarter. ADAR1 Capital Management LLC acquired a new stake in shares of Karyopharm Therapeutics in the 3rd quarter valued at about $164,000. Finally, Bridgeway Capital Management LLC bought a new stake in Karyopharm Therapeutics in the 2nd quarter valued at about $163,000. Institutional investors and hedge funds own 66.44% of the company’s stock.

Karyopharm Therapeutics Trading Up 2.7%

Shares of KPTI stock opened at $5.70 on Friday. Karyopharm Therapeutics has a 1-year low of $3.51 and a 1-year high of $12.97. The stock has a market cap of $97.19 million, a price-to-earnings ratio of -0.39 and a beta of 0.35. The stock has a 50-day moving average of $5.97 and a 200-day moving average of $5.33.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($3.82) EPS for the quarter, missing analysts’ consensus estimates of ($3.30) by ($0.52). The company had revenue of $44.04 million during the quarter, compared to the consensus estimate of $39.56 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Karyopharm Therapeutics will post -0.71 earnings per share for the current year.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).